MAPT and Alzheimer disease: Knowing that the BBB is a remarkable obstacle for the intracranial delivery of therapeutic drugs for neurodegenerative diseases, such as AD, Wasielewska and colleagues developed, in 2022, a sporadic AD BBB model for the ultrasound-mediated delivery of aducanumab and anti-tau antibodies [164].